Remifentanil versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial [ISRCTN43755713]

Bernd Muellejans, Angel López, Michael H Cross, César Bonome, Lachlan Morrison, Andrew J T Kirkham, Bernd Muellejans, Angel López, Michael H Cross, César Bonome, Lachlan Morrison, Andrew J T Kirkham

Abstract

Introduction: This double-blind, randomized, multicentre study was conducted to compare the efficacy and safety of remifentanil and fentanyl for intensive care unit (ICU) sedation and analgesia.

Methods: Intubated cardiac, general postsurgical or medical patients (aged >/= 18 years), who were mechanically ventilated for 12-72 hours, received remifentanil (9 microgram/kg per hour; n = 77) or fentanyl (1.5 microgram/kg per hour; n = 75). Initial opioid titration was supplemented with propofol (0.5 mg/kg per hour), if required, to achieve optimal sedation (i.e. a Sedation-Agitation Scale score of 4).

Results: The mean percentages of time in optimal sedation were 88.3% for remifentanil and 89.3% for fentanyl (not significant). Patients with a Sedation-Agitation Scale score of 4 exhibited significantly less between-patient variability in optimal sedation on remifentanil (variance ratio of fentanyl to remifentanil 1.84; P = 0.009). Of patients who received fentanyl 40% required propofol, as compared with 35% of those who received remifentanil (median total doses 683 mg and 378 mg, respectively; P = 0.065). Recovery was rapid (median time to extubation: 1.1 hours for remifentanil and 1.3 hours for fentanyl; not significant). Remifentanil patients who experienced pain did so for significantly longer during extubation (6.5% of the time versus 1.4%; P = 0.013), postextubation (10.2% versus 3.6%; P = 0.001) and post-treatment (13.5% versus 5.1%; P = 0.001), but they exhibited similar haemodynamic stability with no significant differences in adverse event incidence.

Conclusion: Analgesia based sedation with remifentanil titrated to response provided effective sedation and rapid extubation without the need for propofol in most patients. Fentanyl was similar, probably because the dosing algorithm demanded frequent monitoring and adjustment, thereby preventing over-sedation. Rapid offset of analgesia with remifentanil resulted in a greater incidence of pain, highlighting the need for proactive pain management when transitioning to longer acting analgesics, which is difficult within a double-blind study but would be quite possible under normal circumstances.

Figures

Figure 1
Figure 1
Dosing algorithm: maintenance phase. SAS, Sedation–Agitation Scale.

References

    1. Carrasco G, Cabre L, Sobrepere G, Costa J, Molina R, Cruspinera A, Lacasa C. Synergistic sedation with propofol and midazolam in intensive care patients after coronary artery bypass grafting. Crit Care Med. 1998;2:844–851. doi: 10.1097/00003246-199805000-00015.
    1. Carrasco G, Molina R, Costa J, Soler J-M, L Cabre. Propofol vs midazolam in short-, medium- and long-term sedation of critically ill patients. Chest. 1993;103:557–564.
    1. Westmoreland CL, Hoke JF, Sebel PS, Hug CC, Jr, Muir KT. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GR90291) in patients undergoing elective surgery. Anesthesiology. 1993;79:893–903.
    1. Kapila A, Glass PS, Jacobs JR, Muir KT, Hermann DJ, Shiraishi M, Howell S, Smith RL. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology. 1995;83:968–975. doi: 10.1097/00000542-199511000-00009.
    1. Park GR, Evans TN. Remifentanil in the critically ill – what will its place be? Br J Intensive Care. 1996;6:330–336.
    1. Szalados JE, Boysen PG. Sedation in the critically ill patient. Curr Opin Anaesthesiol. 1998;11:147–155. doi: 10.1097/00001503-199804000-00006.
    1. Lenhart A. Remifentanil in intensive care medicine. J Anasth Intensivbehandl. 2000;7:123–124.
    1. Mastronardi P, Cafiero T, De Cillis P. Remifentanil in anesthesia and intensive care. Minerva Anestesiol. 2000;66:417–423.
    1. Lane M, Cadman B, Park G. Learning to use remifentanil routinely in the critically ill. Care Crit Ill. 2002;18:140–143.
    1. Lane M, Cadman B, Park G. The use of remifentanil in the critically ill. Care Crit Ill. 2002;18:144–145.
    1. Lane M, Cadman B, Park G. Sedation and analgesia in the critically ill patient using remifentanil: frequently asked questions and their answers. Care Crit Ill. 2002;18:146–147.
    1. Park G. Improving sedation and analgesia in the critically ill. Minerva Anestesiol. 2002;68:505–512.
    1. Tipps LB, Coplin WM, Murry KR, Rhoney DH, Gelmont D, Cucchiara RF, Macdonald RL, Muizelaar JP. Safety and feasibility of continuous infusion of remifentanil in the neurosurgical intensive care unit. Neurosurgery. 2000;46:596–602.
    1. Karabinis A, Hantson P, Speelberg B, Stergiopoulos S, Illievich UM, Maas A, Upadhyaya BK. A remifentanil-based technique for analgesia and sedation in ICU patients with neurotrauma: preliminary data [abstract A549] Intensive Care Med. 2001;Suppl 2:S275.
    1. Soltész S, Biedler A, Silomon M, Schopflin I, Molter GP. Recovery after remifentanil and sufentanil for analgesia and sedation of mechanically ventilated patients after trauma or major surgery. Br J Anaesth. 2001;86:763–768. doi: 10.1093/bja/86.6.763.
    1. Breen D, Wilmer A, Bodenham A, Bach V, Bonde J, Kessler P, Albrecht S, Shaikh S. The offset of pharmacodynamic effects of remifentanil in ICU patients is not affected by renal impairment [abstract A284] Intensive Care Med. 2001;Suppl 2:S207.
    1. Breen D, Wilmer A, Kessler P, Bach V. Lower requirement for sedative with a remifentanil-based analgesia/sedation technique in ICU patients [abstract A701] Intensive Care Med. 2002;Supp 1:S180.
    1. Hoke JF, Shlugman D, Dershwitz M, Michalowski P, Malthouse-Dufore S, Connors PM. Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Anesthesiology. 1997;87:533–541. doi: 10.1097/00000542-199709000-00012.
    1. Main A. Remifentanil as an analgesic in the critically ill. Anaesthesia. 1998;53:823–824. doi: 10.1046/j.1365-2044.1998.0584a.x.
    1. Wilhelm W, Dorscheid E, Schlaich N, Niederprum P, Deller D. The use of remifentanil in critically ill patients. An initial clinical experience report. Anaesthesist. 1999;48:625–629. doi: 10.1007/s001010050762.
    1. De Bellis P, Gerbi G, Pacigalupo P, Buscaglia G, Massobrio B, Montagnani L, Servirei L. Experience with remifentanil in the intensive care unit. Minerva Anestesiol. 2002;68:765–773.
    1. Cavaliere F, Antonelli M, Arcangeli A, Conti G, Costa R, Pennisi MA, Proietti R. A low-dose remifentanil infusion is well tolerated for sedation in mechanically ventilated, critically ill patients. Can J Anesth. 2002;49:1088–1094.
    1. Reeker W, Hanel F, Detsch O, Mollenberg O, Werner C, Kochs E. The effects of remifentanil on systemic hemodynamic and EEG responses during endotracheal suctioning in ICU patients [abstract A203] Anesthesiology. 1997;87:A203.
    1. Gupta S, Ravalia A. Remifentanil for percutaneous tracheostomies in ITU. Anaesthesia. 2000;55:491–492.
    1. Kessler P, Chinachoti T, Van Deer Berg P, Stanley A, Kirkham A. Remifentanil vs. morphine for the provision of optimal sedation in ICU patients [abstract A406] Intensive Care Med. 2001;Suppl 2:S239.
    1. Quinton P, Fletcher N, Royston D, Farrimond J, Riedel B. Propofol sparing effect of remifentanil when added to propofol for sedation in the intensive care unit [abstract A352] Intensive Care Med. 2000;Suppl 3:S304.
    1. Park GR, Evans TN, Hutchins J, Borissov B, Gunning KE, Klinck JR. Reducing the demand for admission to intensive care after major abdominal surgery by a change in anaesthetic practice and the use of remifentanil. Eur J Anaesthesiol. 2000;17:111–119. doi: 10.1046/j.1365-2346.2000.00618.x.
    1. Le Gall J-R, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–2963. doi: 10.1001/jama.270.24.2957.
    1. Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation–Agitation Scale for adult critically ill patients. Crit Care Med. 1999;27:1325–1329. doi: 10.1097/00003246-199907000-00022.
    1. Higgins TL, Vared J-P, Estafanous FG, Coyle JP, Ko HK, Goodall DB. Propofol versus midazolam for intensive care unit sedation after coronary artery bypass grafting. Crit Care Med. 1994;22:1415–1423.
    1. Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology. 1996;84:812–820. doi: 10.1097/00000542-199604000-00008.
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir